Quantcast

Latest Sipuleucel-T Stories

2009-07-27 07:00:00

Emerging Therapies to Treat Metastatic Hormone-Refractory Prostate Cancer Will Capture More Than One-Third of the Market, According to a New Report from Decision Resources WALTHAM, Mass., July 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that $2 billion growth in the prostate cancer drug market though 2018 will be driven principally by the launch of emerging therapies in the metastatic...

2009-06-01 11:46:00

SAN FRANCISCO, June 1 /PRNewswire/ -- The markets closed out May in positive territory following on from their April performance...which was their best month in nine years. The Dow Jones industrial average posted its third straight monthly gain closing up 4 percent with the Nasdaq close behind - up 3.3 percent in May. The positive market trend helped biotech with the Burrill Biotech Select Index posting a modest monthly gain of 0.4 percent. "There is just a glimmer of an upward trend for...

2009-05-13 10:08:00

SEATTLE, May 13 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today the closing of its previously reported underwritten public offering of 10,700,000 shares of its common stock, which shares were offered for sale to the public at $19.20 per share. On May 8, 2009, Deutsche Bank Securities Inc., acting as sole manager of the offering, exercised in full its over-allotment option to purchase an additional 1,279,166 shares of common stock at the public offering price of...

2009-05-08 05:30:00

SEATTLE, May 8 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today the pricing of an underwritten public offering of 10,700,000 shares of its common stock. Deutsche Bank Securities will act as sole manager for the offering. Dendreon has granted Deutsche Bank Securities an option to purchase an additional 1,279,166 shares of common stock to cover over-allotments, if any. Dendreon intends to use the net proceeds of the offering to develop manufacturing facilities,...

2009-05-06 06:30:00

SEATTLE, May 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2009. Revenue for the first quarter of 2009 was $30,000 compared to $31,000 for the quarter ended March 31, 2008. Dendreon's total operating expenses for the three months ended March 31, 2009 were $17.0 million compared to $19.2 million for the same period in 2008. The net loss for the quarter ended March 31, 2009 was $15.4 million, or $0.16 per share...

2009-05-05 10:48:49

U.S. scientists have determined sipuleucel-T, a prostate cancer immunotherapy drug, significantly prolongs survival in men with advanced prostate cancer. A Phase 3 trial showed sipuleucel-T (Provenge) improved survival in men with metastatic disease. The Seattle-based Dendreon Corp., manufacturer of the drug, said compared with placebo, sipuleucel-T extended median survival by 4.1 months and improved three-year survival by 38 percent. The researchers said Sipuleucel-T successfully exceeded...

2009-04-30 06:00:00

VALLEY COTTAGE, N.Y., April 30 /PRNewswire/ -- Less than two weeks ago, early on April 15th, Stock Preacher, in their Stock Talk section, posted a Special Technical Report on Dendreon Corporation (Nasdaq: DNDN), which we have been watching since 2007, when we first learned about it. On April 14, DNDN gapped open on positive news from the previous day's close of 7.30/shr, to 16.00/shr, ran to 22.00/shr and closed at 16.99/shr + 9.69 (132%) on 65,345,600/shrs on the day, and since has traded...

5591281daa538c6da19f9de3add8d7bd1
2009-04-29 06:44:02

According to a report released on Tuesday, a new approach to fighting prostate cancer extended the lives of men suffering from the disease. The treatment, Dendreon Corp's Provenge vaccine, trains the immune system to fight tumors. Although Provenge is called a "vaccine," it treats the disease rather than preventing it. The therapy is the first successful attempt to improve survival in late-stage testing.  Doctors have been working towards this goal for decades. "There have been a lot of...

2009-04-28 17:12:00

Phase 3 IMPACT Trial Results to be presented during late-breaking session at AUA Annual Scientific Meeting CHICAGO, April 28 /PRNewswire-USNewswire/ -- Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago. These data from the Phase 3 Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT) study were...

2009-04-28 13:00:00

- Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo - - First Active Cellular Immunotherapy for Cancer to Prolong Survival - - Company to Host Webcast at 5:30 pm ET - CHICAGO and SEATTLE, April 28 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that its pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of significantly improving overall...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.